Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EPHB4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EPHB4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EPHB4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EPHB4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004677710 | Esophagus | ESCC | protein autophosphorylation | 138/8552 | 227/18723 | 2.98e-06 | 3.38e-05 | 138 |
GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
GO:000166720 | Esophagus | ESCC | ameboidal-type cell migration | 250/8552 | 475/18723 | 1.22e-03 | 5.97e-03 | 250 |
GO:00182124 | Esophagus | ESCC | peptidyl-tyrosine modification | 202/8552 | 378/18723 | 1.34e-03 | 6.39e-03 | 202 |
GO:00181084 | Esophagus | ESCC | peptidyl-tyrosine phosphorylation | 200/8552 | 375/18723 | 1.60e-03 | 7.45e-03 | 200 |
GO:000740915 | Esophagus | ESCC | axonogenesis | 219/8552 | 418/18723 | 3.14e-03 | 1.31e-02 | 219 |
GO:00480133 | Esophagus | ESCC | ephrin receptor signaling pathway | 33/8552 | 51/18723 | 4.77e-03 | 1.85e-02 | 33 |
GO:001063120 | Esophagus | ESCC | epithelial cell migration | 187/8552 | 357/18723 | 6.05e-03 | 2.23e-02 | 187 |
GO:009013220 | Esophagus | ESCC | epithelium migration | 188/8552 | 360/18723 | 6.96e-03 | 2.54e-02 | 188 |
GO:009013020 | Esophagus | ESCC | tissue migration | 190/8552 | 365/18723 | 7.91e-03 | 2.82e-02 | 190 |
GO:00467775 | Liver | HCC | protein autophosphorylation | 123/7958 | 227/18723 | 2.40e-04 | 1.80e-03 | 123 |
GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
GO:000166721 | Liver | HCC | ameboidal-type cell migration | 226/7958 | 475/18723 | 1.35e-02 | 4.81e-02 | 226 |
GO:00467779 | Oral cavity | OSCC | protein autophosphorylation | 123/7305 | 227/18723 | 2.31e-06 | 2.93e-05 | 123 |
GO:003367418 | Oral cavity | OSCC | positive regulation of kinase activity | 228/7305 | 467/18723 | 8.31e-06 | 8.90e-05 | 228 |
GO:000166719 | Oral cavity | OSCC | ameboidal-type cell migration | 228/7305 | 475/18723 | 3.46e-05 | 3.10e-04 | 228 |
GO:001063118 | Oral cavity | OSCC | epithelial cell migration | 174/7305 | 357/18723 | 1.04e-04 | 7.70e-04 | 174 |
GO:009013218 | Oral cavity | OSCC | epithelium migration | 175/7305 | 360/18723 | 1.18e-04 | 8.54e-04 | 175 |
GO:009013018 | Oral cavity | OSCC | tissue migration | 176/7305 | 365/18723 | 1.92e-04 | 1.29e-03 | 176 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EPHB4 | SNV | Missense_Mutation | rs146064780 | c.1331G>A | p.Arg444Gln | p.R444Q | P54760 | protein_coding | tolerated(0.41) | benign(0.213) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
EPHB4 | SNV | Missense_Mutation | | c.1676N>T | p.Ala559Val | p.A559V | P54760 | protein_coding | tolerated(0.54) | possibly_damaging(0.89) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EPHB4 | SNV | Missense_Mutation | | c.1216N>A | p.Val406Ile | p.V406I | P54760 | protein_coding | tolerated(0.94) | benign(0.309) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
EPHB4 | SNV | Missense_Mutation | | c.2272N>C | p.Asp758His | p.D758H | P54760 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
EPHB4 | SNV | Missense_Mutation | novel | c.1926N>A | p.Ser642Arg | p.S642R | P54760 | protein_coding | deleterious(0.02) | benign(0.154) | TCGA-OL-A6VQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EPHB4 | deletion | Frame_Shift_Del | novel | c.2029delN | p.Ile677SerfsTer14 | p.I677Sfs*14 | P54760 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
EPHB4 | deletion | Frame_Shift_Del | novel | c.1396delN | p.Asp466ThrfsTer20 | p.D466Tfs*20 | P54760 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
EPHB4 | deletion | Frame_Shift_Del | novel | c.2586delN | p.Asn862LysfsTer16 | p.N862Kfs*16 | P54760 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
EPHB4 | SNV | Missense_Mutation | rs773050327 | c.2930C>T | p.Pro977Leu | p.P977L | P54760 | protein_coding | deleterious(0) | benign(0.015) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EPHB4 | SNV | Missense_Mutation | novel | c.2347C>T | p.Pro783Ser | p.P783S | P54760 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2050 | EPHB4 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | CHEMBL3544983 | TESEVATINIB | |
2050 | EPHB4 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | | XL647 | TESEVATINIB | |
2050 | EPHB4 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | XL647 | TESEVATINIB | |
2050 | EPHB4 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | CHEMBL24828 | VANDETANIB | |
2050 | EPHB4 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | CHEMBL403989 | TG100-801 | |
2050 | EPHB4 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | | KD019 | TESEVATINIB | |
2050 | EPHB4 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | XL647 | TESEVATINIB | |
2050 | EPHB4 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | 249565821 | | |
2050 | EPHB4 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | 249565627 | TESEVATINIB | |
2050 | EPHB4 | KINASE, TYROSINE KINASE, DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | CHEMBL3545155 | JI-101 | |